Seeking Alpha

Novartis (NVS) says that the latest results from two Phase III clinical trials further the...

Novartis (NVS) says that the latest results from two Phase III clinical trials further the benefits of Tasigna over Glivec tablets for the treatment of Philadelphia chronic myeloid leukemia. Patients using Tasigna achieved significantly deeper molecular response versus Glivec, and the data suggests a correlation between early molecular response at three and six months and survival outcome for newly diagnosed patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector